Lv6
2276 积分 2021-08-29 加入
Immunogenicity of biologics delivered in the subcutaneous space: Delineating the contributing factors
6天前
已完结
Recommendations on the Implementation of Performance Outcome Assessments in Clinical Trials: A Good Practices Report of an ISPOR Task Force
15天前
已完结
Case Studies in Identifying and Understanding Seizure Liability in Drug Development
16天前
已完结
Re-evaluating antibody–drug conjugate linker stability: assessment, interpretation, and clinical translation
18天前
已完结
Globally harmonized specifications: Implementing a patient-centric, enhanced control strategy – a meeting report
18天前
已完结
The case for model-informed vaccine development
19天前
已完结
Oncology Drug Development: Challenges of Increasingly Available Therapies
26天前
已关闭
Perspective on Pharmacokinetic Comparability for Biologics Development
26天前
已完结
Four Decades of History & Evolution of Clinical Pharmacology at US Food and Drug Administration (FDA)—Part II: Dose Individualization and Approvability Evidence
1个月前
已完结
Four decades of History & Evolution of Clinical Pharmacology at US Food and Drug Administration (FDA)– Part I: Product Quality
1个月前
已完结
皖公网安备34019202002308
